HPMA copolymers for masking and retargeting of therapeutic viruses

被引:60
作者
Fisher, Kerry D. [1 ]
Seymour, Leonard W. [1 ]
机构
[1] Univ Oxford, Dept Clin Pharmacol, Oxford OX3 7DQ, England
关键词
Virus; Viral therapeutics; Vaccine; Vector; Virotherapy; Polymer; Neutralization; POLYMER-COATED ADENOVIRUS; ONCOLYTIC VIROTHERAPY; CIRCULATION TIME; PHASE-II; VECTORS; CANCER; REPLICATION; VACCINE; CELLS; ANTIBODY;
D O I
10.1016/j.addr.2009.12.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hydrophilic polymers are widely used already for steric stabilisation of bioactive proteins, changing their pharmacokinetics and modifying their interactions with the biological environment. Polymers may also be conjugated to biological surfaces, such as viruses, bacteria and mammalian cells, also to endow steric protection and changed properties. Reactive polymers based on N-[2-hydroxypropyl]methacrylamide have shown particular promise for surface coating of viruses, particularly adenovirus. and here we describe the important observations and innovations arising from this combination of chemical and genetic engineering. Adenovirus is a versatile agent that already finds important experimental applications as a recombinant vaccine, and also for cancer therapy, although its activity in both settings is often limited by a potent antibody-neutralising response in humans that is generally not seen in experimental animals. Coating with HPMA copolymers provides protection against neutralisation by antibodies and complement, and covalent linkage of novel ligands to the surface of the polymer can endow new infectious tropisms, mediated through different receptors, that can expand the potential applications of this versatile technology for a range of settings. (C) 2009 Published by Elsevier B.V.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 47 条
[41]   Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components [J].
Subr, Vladimir ;
Kostka, Libor ;
Selby-Milic, Tom ;
Fisher, Kerry ;
Ulbrich, Karel ;
Seymour, Leonard W. ;
Carlisle, Robert C. .
JOURNAL OF CONTROLLED RELEASE, 2009, 135 (02) :152-158
[42]   Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein [J].
Sumida, SM ;
Truitt, DM ;
Lemckert, AAC ;
Vogels, R ;
Custers, JHHV ;
Addo, MM ;
Lockman, S ;
Peter, T ;
Peyerl, FW ;
Kishko, MG ;
Jackson, SS ;
Gorgone, DA ;
Lifton, MA ;
Essex, M ;
Walker, BD ;
Goudsmit, J ;
Havenga, MJE ;
Barouch, DH .
JOURNAL OF IMMUNOLOGY, 2005, 174 (11) :7179-7185
[43]  
Tanaka T, 1996, CANCER RES, V56, P1341
[44]   Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects [J].
Thorne, SH ;
Hermiston, T ;
Kirn, D .
SEMINARS IN ONCOLOGY, 2005, 32 (06) :537-548
[45]   Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination:: Efficient human cell infection and bypass of preexisting adenovirus immunity [J].
Vogels, R ;
Zuijdgeest, D ;
van Rijnsoever, R ;
Hartkoorn, E ;
Damen, I ;
de Béthune, MP ;
Kostense, S ;
Penders, G ;
Helmus, N ;
Koudstaal, W ;
Cecchini, M ;
Wetterwald, A ;
Sprangers, M ;
Lemckert, A ;
Ophorst, O ;
Koel, B ;
van Meerendonk, M ;
Quax, P ;
Panitti, L ;
Grimbergen, J ;
Bout, A ;
Goudsmit, J ;
Havenga, M .
JOURNAL OF VIROLOGY, 2003, 77 (15) :8263-8271
[46]   Adenovirus serotype 5 hexon mediates liver gene transfer [J].
Waddington, Simon N. ;
McVey, John H. ;
Bhella, David ;
Parker, Alan L. ;
Barker, Kristeen ;
Atoda, Hideko ;
Pink, Rebecca ;
Buckley, Suzanne M. K. ;
Greig, Jenny A. ;
Denby, Laura ;
Custers, Jerome ;
Morita, Takashi ;
Francischetti, Ivo M. B. ;
Monteiro, Robson Q. ;
Barouch, Dan H. ;
van Rooijen, Nico ;
Napoli, Claudio ;
Hlavenga, Menzo J. E. ;
Nicklin, Stuart A. ;
Baker, Andrew H. .
CELL, 2008, 132 (03) :397-409
[47]  
Wong SP, 2009, CURR OPIN MOL THER, V11, P433